P3 Health Partners Inc. 2025 Financial Results Summary

This report explains P3 Health Partners’ latest news in plain English. We have removed the complex jargon so you can understand what is happening and why it matters for your investment decisions.

---

1. What happened?

On March 26, 2026, P3 Health Partners released its 2025 financial results. The company reported a $323.1 million loss. This result was driven by high medical costs and the significant expense of exiting unprofitable markets.

Revenue reached $1.38 billion as the company intentionally moved away from low-profit contracts. Management spent the year reorganizing, which included exiting specific regions and ending unprofitable agreements. This caused their patient base to shrink from 126,000 in 2024 to 116,000 in 2025. The company’s strategy is to prioritize higher-quality earnings over total member volume.

2. The Big Goal: Turning the Corner

The most important takeaway is the company’s outlook for 2026. CEO Aric Coffman stated that the "heavy lifting" of restructuring is finished.

P3 expects a massive improvement in core earnings (Adjusted EBITDA). They are targeting a range between a $20 million loss and a $40 million profit. If they hit the midpoint—a $10 million profit—it would be a $170 million improvement over their 2025 loss of $160 million. This goal depends entirely on the company’s ability to lower medical costs by managing patient care more efficiently.

3. Why does this matter?

Think of P3 as a company that has been in "repair mode." They are focusing on smart growth rather than just adding as many patients as possible.

• For Investors: The stock market dislikes uncertainty. By providing a clear path to profit for 2026, P3 hopes to show that the worst is over. However, cash remains a concern. Their cash dropped from $38.8 million at the end of 2024 to $25 million by December 31, 2025. Investors are watching to see if the company can reach its profit target without issuing more shares—which dilutes your ownership—or taking on more debt.
• For Patients and Employees: P3 is leaving regions where they could not manage costs effectively. They are now focusing on core markets with established partnerships. While this creates a more stable company, it also meant that patients in exited regions had to find new providers, and employees in those areas faced layoffs.

4. What should you watch for?

• The Profitability Test: The 2026 goal assumes a significant drop in medical costs per patient. Watch quarterly updates to see if they hit their monthly targets. If they miss, their cost-saving measures may not be working.
• Cash Flow: Keep a close eye on the cash used for daily operations. If the cash balance falls below $15 million in the next two quarters, the risk of a cash shortage increases significantly.
• Market Reaction: Expect price swings. Traders will weigh the $323.1 million loss against the 2026 turnaround plan. Watch for institutional buying or selling as a sign of market confidence.

5. What happens next?

The company held a conference call on March 26, 2026, to explain their cost-cutting measures. Your next step is to monitor their quarterly reports (10-Q filings) for 2026. If the stock price stabilizes and cash levels hold steady, it suggests the market believes the turnaround is real. If the stock continues to fall, the market remains skeptical of their ability to reach profitability without raising more capital.

---

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.